Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides

Microbes and Infection

Volumn 15, Issue 13, 2013, Pages 874-886

  Watanabe, Koji ^a,b   Murakoshi, Hayato ^a   Tamura, Yoshiko ^a   Koyanagi, Madoka ^a   Chikata, Takayuki ^a   Gatanaga, Hiroyuki ^a,b   Oka, Shinichi ^a,b   Takiguchi, Masafumi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cross clade; CTL; Epitope; HIV; HLA

Indexed keywords

CROSS CLADE CYTOTOXICITY T CELL EPITOPE; EPITOPE; GAG PROTEIN; HLA A ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEF PROTEIN; POL PROTEIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; JAPANESE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CROSS-CLADE; CTL; EPITOPE; HIV; HLA;

CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GENOTYPE; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; JAPAN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84888055664     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.08.002     Document Type: Article

References (50)

1. Walker B.D., Korber B.T. Immune control of HIV: the obstacles of HLA and viral diversity. Nat. Immunol. 2001, 2:473-475.
2. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220. MOPHTAVEG investigators.
3. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. WHO-UNAIDS Network for HIV isolation and characterisation, global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
4. de Souza M.S., Ratto-Kim S., Chuenarom W., Schuetz A., Chantakulkij S., Nuntapinit B., Valencia-Micolta A., Thelian D., Nitayaphan S., Pitisuttithum P., Paris R.M., Kaewkungwal J., Michael N.L., Rerks-Ngarm S., Mathieson B., Marovich M., Currier J.R., Kim J.H. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 2012, 188:5166-5176. Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators.
5. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., Gilbert P.B., Huang Y., Gurley T.C., Kozink D.M., Marshall D.J., Whitesides J.F., Tsao C.Y., Kaewkungwal J., Nitayaphan S., Pitisuttithum P., Rerks-Ngarm S., Kim J.H., Michael N.L., Tomaras G.D., Montefiori D.C., Lewis G.K., DeVico A., Evans D.T., Ferrari G., Liao H.X., Haynes B.F. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 2012, 86:11521-11532.
6. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
7. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G.H., Nickle D., Rousseau C., Coovadia H., Mullins J.I., Heckerman D., Walker B.D., Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007, 13:46-53.
8. Zuniga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., Sanchez H., Frahm N., Linde C.H., Hewitt H.S., Hildebrand W., Altfeld M., Allen T.M., Walker B.D., Korber B.T., Leitner T., Sanchez J., Brander C. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 2006, 80:3122-3125.
9. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 2000, 97:2709-2714.
10. Turnbull E.L., Lopes A.R., Jones N.A., Cornforth D., Newton P., Aldam D., Pellegrino P., Turner J., Williams I., Wilson C.M., Goepfert P.A., Maini M.K., Borrow P. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J. Immunol. 2006, 176:6130-6146.
11. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H., Blanchard T., Ariyoshi K., Oyugi J., Ngugi E., Bwayo J., MacDonald K.S., McMichael A.J., Plummer F.A. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 1998, 102:1758-1765.
12. Johnson R.P., Trocha A., Yang L., Mazzara G.P., Panicali D.L., Buchanan T.M., Walker B.D. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 1991, 147:1512-1521.
13. McKinney D.M., Skvoretz R., Livingston B.D., Wilson C.C., Anders M., Chesnut R.W., Sette A., Essex M., Novitsky V., Newman M.J. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J. Immunol. 2004, 173:1941-1950.
14. Bennett M.S., Ng H.L., Ali A., Yang O.O. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J. Infect Dis. 2008, 197:390-397.
15. Fukada K., Tomiyama H., Wasi C., Matsuda T., Kusagawa S., Sato H., Oka S., Takebe Y., Takiguchi M. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS 2002, 16:701-711.
16. Cao H., Kanki P., Sankale J.L., Dieng-Sarr A., Mazzara G.P., Kalams S.A., Korber B., Mboup S., Walker B.D. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 1997, 71:8615-8623.
17. Durali D., Morvan J., Letourneur F., Schmitt D., Guegan N., Dalod M., Saragosti S., Sicard D., Levy J.P., Gomard E. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J. Virol. 1998, 72:3547-3553.
18. Chen H., Ndhlovu Z.M., Liu D., Porter L.C., Fang J.W., Darko S., Brockman M.A., Miura T., Brumme Z.L., Schneidewind A., Piechocka-Trocha A., Cesa K.T., Sela J., Cung T.D., Toth I., Pereyra F., Yu X.G., Douek D.C., Kaufmann D.E., Allen T.M., Walker B.D. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 2012, 13:691-700.
19. Sanou M.P., De Groot A.S., Murphey-Corb M., Levy J.A., Yamamoto J.K. HIV-1 vaccine trials: evolving concepts and designs. Open AIDS J. 2012, 6:274-288.
20. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 2009, 83:8300-8314.
21. Masemola A.M., Mashishi T.N., Khoury G., Bredell H., Paximadis M., Mathebula T., Barkhan D., Puren A., Vardas E., Colvin M., Zijenah L., Katzenstein D., Musonda R., Allen S., Kumwenda N., Taha T., Gray G., McIntyre J., Karim S.A., Sheppard H.W., Gray C.M. HIVNET 028 Study Team, Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J. Immunol. 2004, 173:4607-4617.
22. Roshorm Y., Cottingham M.G., Potash M.J., Volsky D.J., Hanke T. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur. J. Immunol. 2012, 42:3243-3255.
23. Knudsen M.L., Mbewe-Mvula A., Rosario M., Johansson D.X., Kakoulidou M., Bridgeman A., Reyes-Sandoval A., Nicosia A., Ljungberg K., Hanke T., Liljestrom P. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J. Virol. 2012, 86:4082-4090.
24. Rosario M., Borthwick N., Stewart-Jones G.B., Mbewe-Mvula A., Bridgeman A., Colloca S., Montefiori D., McMichael A.J., Nicosia A., Quakkelaar E.D., Drijfhout J.W., Melief C.J., Hanke T. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 2012, 26:275-284.
25. Roshorm Y., Hong J.P., Kobayashi N., McMichael A.J., Volsky D.J., Potash M.J., Takiguchi M., Hanke T. Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge. Eur. J. Immunol. 2009, 39:1831-1840.
26. Cebere I., Dorrell L., McShane H., Simmons A., McCormack S., Schmidt C., Smith C., Brooks M., Roberts J.E., Darwin S.C., Fast P.E., Conlon C., Rowland-Jones S., McMichael A.J., Hanke T. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24:417-425.
27. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., Pinheiro S., Gillespie G., Brown D., Loach V., Roberts J., Guimaraes-Walker A., Hayes P., Loughran K., Smith C., De Bont J., Verlinde C., Vooijs D., Schmidt C., Boaz M., Gilmour J., Fast P., Dorrell L., Hanke T., McMichael A.J. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 2006, 80:4717-4728.
28. Mwau M., Cebere I., Sutton J., Chikoti P., Winstone N., Wee E.G., Beattie T., Chen Y.H., Dorrell L., McShane H., Schmidt C., Brooks M., Patel S., Roberts J., Conlon C., Rowland-Jones S.L., Bwayo J.J., McMichael A.J., Hanke T. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004, 85:911-919.
29. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., Livingston B.D., Villafana T.L., Li H., Noonan E., Russell N.D. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26:215-223. HIV Vaccine Trial Network.
30. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., Weinhold K.J., Ferrari G., Parker S.D., McElrath M.J., Frey S.E., Fuchs J.D., Keefer M.C., Lubeck M.D., Egan M., Braun R., Eldridge J.H., Haynes B.F., Corey L. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27:243-249. NIAID HIV Vaccine Trials Network.
31. Salmon-Ceron D., Durier C., Desaint C., Cuzin L., Surenaud M., Hamouda N.B., Lelievre J.D., Bonnet B., Pialoux G., Poizot-Martin I., Aboulker J.P., Levy Y., Launay O. ANRS VAC trial group, immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24:2211-2223.
32. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., Bashir F., Bhatt K., Ogutu H., Wakasiaka S., Matu L., Waruingi W., Odada J., Oyaro M., Indangasi J., Ndinya-Achola J., Konde C., Mugisha E., Fast P., Schmidt C., Gilmour J., Tarragona T., Smith C., Barin B., Dally L., Johnson B., Muluubya A., Nielsen L., Hayes P., Boaz M., Hughes P., Hanke H., McMichael A., Bwayo J., Kaleebu P. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26:2788-2795.
33. Watanabe T., Murakoshi H., Gatanaga H., Koyanagi M., Oka S., Takiguchi M. Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B *4002-restricted T cells. Microbe. Infect. 2011, 13:160-166.
34. Karaki S., Kariyone A., Kato N., Kano K., Iwakura Y., Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993, 37:139-142.
35. Koizumi H., Iwatani T., Tanuma J., Fujiwara M., Izumi T., Oka S., Takiguchi M. Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors. Microbe. Infect. 2009, 11:198-204.
36. Yagita Y., Kuse N., Kuroki K., Gatanaga H., Carlson J.M., Chikata T., Brumme Z.L., Murakoshi H., Akahoshi T., Pfeifer N., Mallal S., John M., Ose T., Matsubara H., Kanda R., Fukunaga Y., Honda K., Kawashima Y., Ariumi Y., Oka S., Maenaka K., Takiguchi M. Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity. J. Virol. 2013, 87:2253-2263.
37. Sato H., Tomita Y., Ebisawa K., Hachiya A., Shibamura K., Shiino T., Yang R., Tatsumi M., Gushi K., Umeyama H., Oka S., Takebe Y., Nagai Y. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J. Virol. 2001, 75:5604-5613.
38. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
39. Akahoshi T., Chikata T., Tamura Y., Gatanaga H., Oka S., Takiguchi M. Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes. J. Virol. 2012, 86:1971-1981.
40. Karlsson A.C., Iversen A.K., Chapman J.M., de Oliviera T., Spotts G., McMichael A.J., Davenport M.P., Hecht F.M., Nixon D.F. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One 2007, 2:e225.
41. Kantakamalakul W., de Souza M., Bejrachandra S., Ampol S., Cox J., Sutthent R. Identification of a novel HIV type 1 CRF01_AE cytotoxic T lymphocyte (CTL) epitope restricted by an HLA-Cw0602 allele and a novel HLA-A0206/peptide restriction. AIDS Res. Hum. Retroviruses 2006, 22:1271-1282.
42. Li F., Finnefrock A.C., Dubey S.A., Korber B.T., Szinger J., Cole S., McElrath M.J., Shiver J.W., Casimiro D.R., Corey L., Self S.G. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011, 6:e20479.
43. Sabbaj S., Bansal A., Ritter G.D., Perkins C., Edwards B.H., Gough E., Tang J., Szinger J.J., Korber B., Wilson C.M., Kaslow R.A., Mulligan M.J., Goepfert P.A. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J. Acquir. Immune Defic. Syndr. 2003, 33:426-438.
44. Altfeld M., Addo M.M., Eldridge R.L., Yu X.G., Thomas S., Khatri A., Strick D., Phillips M.N., Cohen G.B., Islam S.A., Kalams S.A., Brander C., Goulder P.J., Rosenberg E.S., Walker B.D. Vpr is preferentially targeted by CTL during HIV-1 infection. J. Immunol. 2001, 167:2743-2752. HIV Study Collaboration.
45. Hossain M.S., Tomiyama H., Inagawa T., Ida S., Oka S., Takiguchi M. Identification and characterization of HLA-A*3303-restricted, HIV type 1 Pol- and Gag-derived cytotoxic T cell epitopes. AIDS Res. Hum. Retroviruses 2003, 19:503-510.
46. Falk K., Rotzschke O., Takiguchi M., Grahovac B., Gnau V., Stevanovic S., Jung G., Rammensee H.G. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 1994, 40:238-241.
47. Ikeda-Moore Y., Tomiyama H., Miwa K., Oka S., Iwamoto A., Kaneko Y., Takiguchi M. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J. Immunol. 1997, 159:6242-6252.
48. Fujiwara M., Tanuma J., Koizumi H., Kawashima Y., Honda K., Mastuoka-Aizawa S., Dohki S., Oka S., Takiguchi M. Different abilities of escape mutant-specific cytotoxic T cells to suppress replication of escape mutant and wild-type human immunodeficiency virus type 1 in new hosts. J. Virol. 2008, 82:138-147.
49. Brander C., Yang O.O., Jones N.G., Lee Y., Goulder P., Johnson R.P., Trocha A., Colbert D., Hay C., Buchbinder S., Bergmann C.C., Zweerink H.J., Wolinsky S., Blattner W.A., Kalams S.A., Walker B.D. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J. Virol. 1999, 73:10191-10198.
50. Buranapraditkun S., Hempel U., Pitakpolrat P., Allgaier R.L., Thantivorasit P., Lorenzen S.I., Sirivichayakul S., Hildebrand W.H., Altfeld M., Brander C., Walker B.D., Phanuphak P., Hansasuta P., Rowland-Jones S.L., Allen T.M., Ruxrungtham K. A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais. PLoS One 2011, 6:e23603.